银屑病患者皮肤生物制剂治疗降低银屑病关节炎发生率
该回顾性队列研究纳入1719例无PsA的银屑病患者,比较局部治疗/无治疗、传统DMARDs和生物制剂对PsA发生率的影响。随访期间239例(14%)发生PsA,生物制剂组PsA风险显著低于局部治疗组(IRR=0.26),调整后生物制剂使用为保护因素(HR: 0.19)。
要点
- 生物制剂治疗银屑病皮肤可显著降低PsA发生风险(HR: 0.19)。
- 男性、甲受累和高BMI与PsA发生风险增加相关。
- 生物制剂与cDMARDs相比PsA风险差异无统计学意义。
核心结论
- 银屑病患者使用生物制剂治疗皮肤可降低PsA发生风险。
研究设计与样本
- 按治疗分为局部治疗/无治疗组(1387例)、cDMARDs组(229例)和bDMARDs组(103例)。
- 采用Cox比例风险模型评估调整后PsA发生风险。
主要发现
- 随访期间239例(14%)发生PsA,其中局部治疗组231例、cDMARDs组6例、bDMARDs组2例。
- 总体PsA发生率为1.6/100患者年。
- bDMARDs组PsA风险显著低于局部治疗组(IRR=0.26; 95%CI 0.03-0.94; p=0.0111)。
- bDMARDs组与cDMARDs组相比PsA风险无显著差异(IRR=0.35; 95%CI 0.035-1.96; p=0.1007)。
- 调整后男性、甲受累和高BMI与PsA风险增加相关,生物制剂使用为保护因素(HR: 0.19; 95%CI 0.05-0.81)。
关键数值与推荐
- 生物制剂使用与PsA风险降低独立相关(HR: 0.19; 95%CI 0.05-0.81)。
临床怎么用
- 对银屑病患者处方皮肤生物制剂时,可能同时降低PsA发生风险。
- 具有男性、甲受累或高BMI等危险因素的患者可能从生物制剂治疗中更多获益。
局限性
- 回顾性队列设计,可能存在混杂和选择偏倚。
- bDMARDs组样本量较小(103例),事件数少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the incidence of psoriatic arthritis (PsA) in patients with psoriasis (PsO) according to different treatments for their skin: topics/no treatment, conventional disease-modifying antirheumatic drugs (DMARDs) (cDMARDs) or biological DMARDs (bDMARDs). METHODS: Patients with PsO without PsA followed at a university hospital were included in this retrospective cohort study. Patients were classified according to their treatment in topics (topics, phototherapy or no treatment), cDMARDs (methotrexate and cyclosporine) and bDMARDs (tumour necrosis factor inhibitors (TNFi), interleukin 17 inhibitors (IL-17i) and IL-12-23i ((interleukin (IL) 12/IL-23 inhibitor))) groups. Incident cases of PsA were attributed to one treatment if developed during the administration of that treatment. A Cox proportional hazards model was used to evaluate the adjusted risk of PsA development by treatment group. RESULTS: 1719 patients with PsO contributed a total of 14 721 patient/years (py). 1387 (81%) patients were in the topics, 229 (13%) in cDMARDs and 103 (6%) in the bDMARDs group. During follow-up, 239 patients (14%) developed PsA (231 under topics, six under cDMARDs and two under bDMARDs). Global incidence was 1.6 per 100 py. The risk of developing PsA in patients with PsO treated with bDMARDs was significantly lower (incidence rate ratio (IRR)=0.26; 95% CI 0.03 to 0.94; p=0.0111), compared with topics, but not compared with cDMARDs (IRR=0.35; 95% CI 0.035 to 1.96; p=0.1007). Adjusted Cox proportional hazards regression analysis showed that male sex, nail involvement and higher body max index were associated with increased risk of developing PsA, while biologics use was protective (HR: 0.19; 95% CI 0.05 to 0.81). CONCLUSION: Treatment with biologics in patients with PsO reduced the risk of PsA development.
引用
- Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2021. PMID: 34281904. doi:10.1136/annrheumdis-2021-220865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。